<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Arial"&gt;&lt;font color="#000000"&gt;&lt;strong&gt;&lt;font face="Calibri"&gt;DEPARTMENT OF HEALTH AND HUMAN SERVICES&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Arial"&gt;&lt;font color="#000000"&gt;&lt;strong&gt;&lt;font face="Calibri"&gt;Food and Drug Administration&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 12pt; mso-bidi-font-family: Arial"&gt;&lt;font color="#000000"&gt;&lt;strong&gt;&lt;font face="Calibri"&gt;[Docket No. FDA&amp;ndash;2010&amp;ndash;N&amp;ndash;0268]&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Arial"&gt;&lt;font color="#000000"&gt;&lt;strong&gt;&lt;font face="Calibri"&gt;Dental Products Panel of the Medical Devices Advisory Committee;&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Arial"&gt;&lt;font color="#000000"&gt;&lt;strong&gt;&lt;font face="Calibri"&gt;Amendment of Notice&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;span&gt;&lt;strong&gt;&lt;font size="3"&gt;AGENCY&lt;/font&gt;: &lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;Food and Drug Administration, HHS.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;span&gt;&lt;strong&gt;&lt;font size="3"&gt;ACTION&lt;/font&gt;: &lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;Notice.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;The Food and Drug Administration (FDA) is announcing an amendment&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;to the notice of meeting of the Dental Products Panel of the Medical Devices&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;span&gt;Advisory Committee. This meeting was announced in the &lt;strong&gt;Federal Register &lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;of&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;June 11, 2010 (75 FR 33315). The amendment is being made to reflect a change&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;in the &lt;/span&gt;&lt;i&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior-Italic"&gt;Agenda &lt;/span&gt;&lt;/i&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;portion of the document. There are no other changes.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;span&gt;&lt;strong&gt;&lt;font size="3"&gt;FOR FURTHER INFORMATION CONTACT&lt;/font&gt;: &lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;Olga I. Claudio, Food and Drug&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;Administration, Center for Devices and Radiological Health, 10903 New&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;Hampshire Ave., Bldg. 66, rm. 1553, Silver Spring, MD 20993&amp;ndash;0002, 301&amp;ndash;796&amp;ndash;&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;7608, or FDA Advisory Committee Information Line, 1&amp;ndash;800&amp;ndash;741&amp;ndash;8138 (301&amp;ndash;&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;443&amp;ndash;0572 in the Washington DC area), code 3014512518. Please call the&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;Information Line for up-to-date information on this meeting.&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;span&gt;&lt;strong&gt;&lt;font size="3"&gt;SUPPLEMENTARY INFORMATION&lt;/font&gt;: &lt;/strong&gt;&lt;/span&gt;&lt;span&gt;In the &lt;strong&gt;Federal Register &lt;/strong&gt;&lt;/span&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;of June 11, 2010, FDA&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;announced that a meeting of the Dental Products Panel of the Medical Devices&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;Advisory Committee would be held on December 14 and 15, 2010. On page&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;33316, in the first column, in the &lt;/span&gt;&lt;i&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior-Italic"&gt;Agenda &lt;/span&gt;&lt;/i&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;portion of the document, in the&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;second full paragraph, in the second sentence, the phrase &amp;lsquo;&amp;lsquo;(docket numbers&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;FDA&amp;ndash;2008&amp;ndash;N&amp;ndash;0163 and FDA&amp;ndash;2009&amp;ndash;P&amp;ndash;0357)&amp;rsquo;&amp;rsquo; is changed to read as follows:&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;span style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/span&gt;&amp;lsquo;&amp;lsquo;(docket numbers FDA&amp;ndash;2008&amp;ndash;N&amp;ndash;0163, FDA&amp;ndash;2009&amp;ndash;P&amp;ndash;0357, and FDA&amp;ndash;&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;2010&amp;ndash;P&amp;ndash;0056&amp;ndash;0001)&amp;rsquo;&amp;rsquo;&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;This notice is issued under the Federal Advisory Committee Act (5 U.S.C.&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 13pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;app. 2) and 21 CFR part 14, relating to the advisory committees.&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 12pt; mso-bidi-font-family: Melior"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;Dated: September 21, 2010.&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;span style="font-size: 12pt; mso-bidi-font-family: Melior-Bold"&gt;&lt;strong&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;Jill Hartzler Warner,&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;i&gt;&lt;span style="font-size: 12pt; mso-bidi-font-family: Melior-Italic"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;Acting Associate Commissioner for Special Medical Programs.&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;i&gt;&lt;span style="font-size: 12pt; mso-bidi-font-family: Melior-Italic"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 0pt; line-height: normal; mso-layout-grid-align: none"&gt;&lt;i&gt;&lt;span style="font-size: 12pt; mso-bidi-font-family: Melior-Italic"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;(Original Notice is as follows)&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin: 0in 0in 10pt"&gt;&lt;o:p&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;&amp;nbsp;&lt;/font&gt;&lt;/o:p&gt;&lt;/p&gt;&lt;p style="text-align: left"&gt;&amp;nbsp;&lt;/p&gt;&lt;p style="text-align: left"&gt;&lt;p style="text-align: left"&gt;&lt;b&gt;DEPARTMENT OF HEALTH AND&lt;/b&gt; &lt;b&gt;HUMAN SERVICES&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p style="text-align: left"&gt;&lt;b&gt;Food and Drug Administration&lt;/b&gt;&lt;/p&gt;&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;&lt;b&gt;[Docket No. FDA&amp;ndash;2010&amp;ndash;N&amp;ndash;0268]&lt;/b&gt; &lt;b&gt;Dental Products Panel of the Medical&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;&lt;b&gt;Devices Advisory Committee; Notice of Meeting&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;&lt;b&gt;AGENCY&lt;/b&gt;&lt;b&gt;: &lt;/b&gt;Food and Drug Administration, HHS.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;&lt;b&gt;ACTION&lt;/b&gt;&lt;b&gt;: &lt;/b&gt;Notice.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;&lt;br /&gt;This notice announces a forthcoming meeting of a public advisory committee&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;of the Food and Drug Administration (FDA). The meeting will be open to the public.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;&lt;br /&gt;&lt;strong&gt;&lt;i&gt;Name of Committee&lt;/i&gt;:&lt;/strong&gt; Dental Products Panel of the Medical Devices Advisory&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;Committee.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;&lt;br /&gt;&lt;strong&gt;&lt;i&gt;General Function of the Committee&lt;/i&gt;:&lt;/strong&gt; To provide advice and recommendations to the agency on&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;FDA's regulatory issues.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;&lt;br /&gt;&lt;strong&gt;&lt;i&gt;Date and Time&lt;/i&gt;:&lt;/strong&gt; The meeting will be held on December 14 and 15, 2010, from&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;8 a.m. to 6 p.m.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;&lt;br /&gt;&lt;strong&gt;&lt;i&gt;Location&lt;/i&gt;:&lt;/strong&gt; Holiday Inn-Gaithersburg, Main Ballroom, 2 Montgomery Village&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;Ave., Gaithersburg, MD 20879.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;&lt;br /&gt;Contact Person: Olga I. Claudio, Food and Drug Administration, Center for Devices and Radiological Health, WO66, rm. 1553, Silver Spring, MD 20993&amp;ndash;0002, 301&amp;ndash;796&amp;ndash;7608&lt;/p&gt;&lt;p style="text-align: left"&gt;or FDA Advisory Committee Information Line, 1&amp;ndash;800&amp;ndash;741&amp;ndash;8138 (301&amp;ndash;443&amp;ndash;0572 in the Washington, DC area), code 301&amp;ndash;451&amp;ndash;2518.&lt;/p&gt;&lt;p style="text-align: left"&gt;Please call the Information Line for up-to-date information on this meeting.&lt;/p&gt;&lt;p style="text-align: left"&gt;A notice in the Federal Register about last minute modifications&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;that impact a previously announced advisory committee meeting cannot&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;always be published quickly enough to provide timely notice. Therefore, you&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;should always check the agency&amp;rsquo;s Web site and call the appropriate advisory&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;committee hot line/phone line to learn about possible modifications before coming to the meeting.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;&lt;br /&gt;Comments: FDA is opening a docket for public comment on this document.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;The docket number is FDA&amp;ndash;2010&amp;ndash;N&amp;ndash;0268. The docket will be open for public&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;comment on June 11, 2010. The docket will close on December 3, 2010.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;Interested persons are encouraged to use the docket to submit either electronic or&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;written comments regarding this meeting. Submit electronic comments to&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;http://www.regulations.gov. Submit written comments to the Division of&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;Dockets Management, Food and Drug Administration, 5630 Fishers Lane, rm.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;1061, Rockville, MD 20852. It is only necessary to send one set of comments.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;It is no longer necessary to send two copies of mailed comments. Identify&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;comments with the docket number found in brackets in the heading of this&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;document. Received comments may be seen in the Division of Dockets&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;Management between 9 a.m. and 4 p.m., Monday through Friday.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;&lt;br /&gt;Agenda: On December 14 and 15, 2010, the committee will discuss and&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;make recommendations on scientific issues raised in petitions received by&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;FDA concerning the final rule on the classification of dental amalgam, which&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;published in the Federal Register on August 4, 2009 (74 FR 38686). These&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;petitions (docket numbers FDA&amp;ndash;2008&amp;ndash;N&amp;ndash;0163 and FDA&amp;ndash;2009&amp;ndash;P&amp;ndash;0357) can be&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;viewed at http://www.regulations.gov/search/Regs/home.html#&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;documentDetail?R=09000064809fbe3f;http://www.regulations.gov/search/&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;Regs/home.html#documentDetail?R=0900006480a1d1bc; http://&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;www.regulations.gov/search/Regshome.html#documentDetail?&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;R=0900006480a24048; and http://www.regulations.gov/search/Regs/&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;home.html#documentDetail?R=0900006480a80ae5. Issues raised in&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;the petitions include the adequacy of the risk assessment performed by FDA&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;in classifying dental amalgam in light of a new report on risk assessments issued&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;by the National Academy of Sciences, entitled &amp;lsquo;&amp;lsquo;Science and Decisions:&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;Advancing Risk Assessment,&amp;rsquo;&amp;rsquo; NAP, 2009. FDA intends to make background&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;material available to the public no later than 2 business days before the meeting.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;If FDA is unable to post the background material on its Web site prior to the&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;meeting, the background material will be made publicly available at the&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;location of the advisory committee meeting, and the background material&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;will be posted on FDA&amp;rsquo;s Web site after the meeting. Background material is&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm.&lt;/p&gt;&lt;p style="text-align: left"&gt;Scroll down to the appropriate advisory committee link.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;Procedure: Interested persons may present data, information, or views,&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;orally or in writing, on issues pending before the committee. Written&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;submissions may be made to the contact person on or before December 6, 2010.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;Oral presentations from the public will be scheduled at 1 p.m. on December 14,&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;2010 and at 8 a.m. on December 15,2010. Those desiring to make formal&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;oral presentations should notify the contact person and submit a brief&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;statement of the general nature of the evidence or arguments they wish to&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;present, the names and addresses of proposed participants, and an&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;indication of the approximate time requested to make their presentation on&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;or before November 29, 2010. Time allotted for each presentation may be&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;limited. If the number of registrants requesting to speak is greater than can&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;be reasonably accommodated during the scheduled open public hearing session,&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;FDA may conduct a lottery to determine the speakers for the scheduled open&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;public hearing session. The contact person will notify interested persons&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;agency is not responsible for providing access to electrical outlets.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;FDA welcomes the attendance of the public at its advisory committee&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;meetings and will make every effort to accommodate persons with physical&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;disabilities or special needs. If you require special accommodations due to&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;a disability, please contact AnnMarie Williams, Conference Management&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;Staff, 301&amp;ndash;796&amp;ndash;5966, at least 7 days in advance of the meeting.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;FDA is committed to the orderly conduct of its advisory committee&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures on&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;public conduct during advisory committee meetings.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;Dated: June 8, 2010.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;Jill Hartzler Warner,&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;Acting Associate Commissioner for Special Medical Programs.&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;[FR Doc. 2010&amp;ndash;14084 Filed 6&amp;ndash;10&amp;ndash;10; 8:45 am]&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;BILLING CODE 4160&amp;ndash;01&amp;ndash;S&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;p style="text-align: left"&gt;&amp;nbsp;&lt;/p&gt;</wcm:element>
</wcm:root>
